The HemOnc Pulse
What Are the Top Questions in ALL?
Oct 19, 2023
Dr. Elias Jabbour, an Associate Editor of Blood Cancers Today, discusses the burning questions in acute lymphoblastic leukemia (ALL). Topics include approaches to treating Philadelphia-negative ALL, measuring MR-D in pH negative disease, treatment options for both younger and older patients with pH negative leukemia, and current treatment options for relapsed disease in ALL.
24:59
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Combining targeted therapies and low-dose chemotherapy has significantly improved survival rates in younger patients with Philadelphia-negative acute lymphoblastic leukemia (ALL).
- New treatment approaches including low-dose chemotherapy and immune therapies have shown promising results in improving outcomes for older patients with Philadelphia-negative ALL.
Deep dives
Advancements in Treatment of PH-Negative ALL for Younger Patients
In the podcast, the speaker discusses the advancements in the treatment of Philadelphia-negative acute lymphoblastic leukemia (ALL) for younger patients. They highlight the use of targeted therapies, including TKIs and immunotherapy, in combination with low-dose chemotherapy. This approach has shown significant improvements in survival rates, with four-year survival reaching 82%. The speaker also emphasizes the importance of measuring minimal residual disease (MRD) using flow cytometry and NGS to assess disease response, guiding treatment decisions. They mention ongoing studies to further explore the role of immunotherapy upfront and reduce chemotherapy in the management of ALL.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
